Medpace Holdings Inc
NASDAQ:MEDP
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
270.58
457.29
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one MEDP stock under the Base Case scenario is 286.45 USD. Compared to the current market price of 337.75 USD, Medpace Holdings Inc is Overvalued by 15%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Medpace Holdings Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for MEDP cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Medpace Holdings Inc
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Medpace Holdings Inc., a prominent player in the global clinical research organization (CRO) space, has made a name for itself by offering comprehensive drug development services tailored to the needs of pharmaceutical and biotechnology companies. Founded in 1992 and headquartered in Cincinnati, Ohio, the company specializes in conducting clinical trials for innovative therapies across various therapeutic areas, including oncology, cardiology, and infectious diseases. With its unique approach to clinical development, Medpace combines deep operational expertise with a commitment to collaboration and transparency, helping clients navigate the complexities of bringing new drugs to market. The c...
Medpace Holdings Inc., a prominent player in the global clinical research organization (CRO) space, has made a name for itself by offering comprehensive drug development services tailored to the needs of pharmaceutical and biotechnology companies. Founded in 1992 and headquartered in Cincinnati, Ohio, the company specializes in conducting clinical trials for innovative therapies across various therapeutic areas, including oncology, cardiology, and infectious diseases. With its unique approach to clinical development, Medpace combines deep operational expertise with a commitment to collaboration and transparency, helping clients navigate the complexities of bringing new drugs to market. The company’s strong track record of successful trial management and regulatory compliance has made it a trusted partner for both established and emerging life sciences firms.
As the demand for efficient and effective clinical trials continues to rise in an increasingly competitive market, Medpace is well-positioned for growth. Its focus on ensuring quality and speed enables clients to make faster decisions, which is essential in today's fast-paced healthcare landscape. The company's robust earnings and consistent revenue growth are indicative of its operational excellence and strategic market partnerships. Moreover, with a broad international reach and an experienced workforce, Medpace is adept at adapting to various regulatory environments, further solidifying its reputation as a leader in the CRO industry. For investors, Medpace presents an opportunity to tap into the expanding biopharmaceutical sector, where innovation and patient-centric care are driving demand for clinical development services.
Medpace Holdings Inc. is a global clinical research organization (CRO) that provides comprehensive services to the pharmaceutical and biotechnology industries. The company focuses on gathering and managing data for clinical trials, and its core business segments can be categorized as follows:
-
Clinical Development Services: This is the primary segment of Medpace, encompassing a wide range of services to support clinical trial operations. This includes study design, site selection, patient recruitment, data collection, and regulatory compliance. Medpace works with both drug and medical device developers in various phases of clinical trials, from preclinical to post-marketing studies.
-
Laboratory Services: Medpace offers lab services that support clinical trials by providing testing and analysis of biological samples. This segment ensures accurate data collection and compliance with regulatory standards, which is crucial for the integrity of clinical studies.
-
Regulatory Affairs and Consulting: Medpace provides guidance and services to its clients for regulatory submissions and compliance, helping them navigate the complexities of requirements from health authorities like the FDA and EMA. Their expertise streamlines the process of bringing new drugs and devices to market.
-
Post-Marketing Services: After a product is launched, Medpace continues to support clients with services related to post-marketing surveillance, including Phase IV clinical trials and observational studies to monitor the effectiveness and safety of products in the general population.
-
Therapeutic Expertise: Medpace has specialized capabilities across various therapeutic areas, including oncology, cardiology, neuroscience, and infectious diseases. This segment highlights the company’s ability to handle trials that require specific knowledge of particular medical conditions and treatments.
These segments collectively position Medpace as a key player in the CRO market, leveraging its integrated services to provide efficiency and expertise throughout the clinical trial process.
Medpace Holdings Inc. employs several unique competitive advantages that help distinguish it from its rivals in the clinical research organization (CRO) market. Here are some key factors:
-
Therapeutic Expertise: Medpace specializes in specific therapeutic areas, providing deep expertise in clinical research across these sectors. This focus allows them to efficiently manage complex clinical trials, attracting sponsors who need specialized knowledge.
-
Integrated Service Model: Medpace offers a comprehensive range of services under one roof, from early-phase drug development to post-market studies. This integrated model enhances operational efficiency and provides clients with a seamless experience.
-
Dedicated Project Teams: Medpace emphasizes building dedicated project teams for each client, enabling better communication, faster decision-making, and a more tailored approach to client needs. This personalized service often leads to higher client satisfaction.
-
Global Reach with Local Expertise: While Medpace operates globally, it also emphasizes local regulatory knowledge and cultural awareness. This capability is essential for navigating the complexities of international clinical trials.
-
Strong Financial Position: As a publicly traded company, Medpace has access to capital, making it better positioned to invest in technology, infrastructure, and workforce, giving it an edge in operational excellence.
-
Technology Utilization: Medpace invests in technology to enhance data collection, management, and reporting processes. Their focus on electronic data capture and real-time analytics can lead to more efficient trial management and timely results.
-
Regulatory Knowledge and Compliance: The company has a strong track record of managing regulatory challenges and ensuring compliance, which is critical in the highly regulated pharmaceutical environment.
-
Client-Centric Approach: Medpace's commitment to understanding and aligning with the specific needs of its clients helps in building long-term relationships, leading to repeat business.
-
Experienced Management Team: The leadership at Medpace has a wealth of experience within the industry, contributing to strategic decision-making and operational success.
These competitive advantages position Medpace favorably in the CRO market, enabling them to attract new clients and maintain existing relationships.
Medpace Holdings Inc, as a full-service clinical contract research organization (CRO), operates in a dynamic and competitive industry. Here are some key risks and challenges the company may face in the near future:
-
Regulatory Compliance: The clinical research industry is heavily regulated. Any changes in regulations, such as those related to FDA guidelines or international regulatory standards, can impact Medpace's operations and client relationships.
-
Market Competition: The CRO market is highly competitive, with numerous players ranging from small specialized firms to large multinational organizations. Increased competition can lead to pricing pressures and loss of market share.
-
Recruitment and Retention of Talent: The success of clinical trials relies heavily on skilled professionals. Challenges in hiring and retaining qualified personnel could affect the company’s ability to execute trials effectively.
-
Economic Environment: Economic downturns or uncertainties can lead to reduced R&D budgets from pharmaceutical and biotech companies, resulting in delayed or cancelled projects.
-
Technological Changes: Rapid advancements in technology, including data management and analysis tools, need to be continuously adopted. Failing to keep pace with technological progress could hinder Medpace’s competitiveness.
-
Client Dependency: If Medpace relies heavily on a small number of clients for a significant portion of its revenue, it may face financial challenges if these clients decide to move their business elsewhere.
-
Global Market Dynamics: International operations expose Medpace to geopolitical risks, currency fluctuations, and varying regulatory environments that could impact profitability.
-
Public Health Events: Events such as the COVID-19 pandemic can disrupt clinical trials and initiate unforeseen challenges in recruitment and transport.
-
Data Security and Privacy: With the increasing amount of data collected in clinical trials, ensuring data security and compliance with privacy regulations (like GDPR) is critical to avoid legal and reputational risks.
-
Investor Expectations: As a publicly traded company, maintaining investor confidence and meeting earnings expectations can influence stock performance and overall company valuation.
Addressing these challenges effectively will require strategic planning, investment in technology and talent, and strong operational management to maintain competitiveness in the CRO landscape.
Revenue & Expenses Breakdown
Medpace Holdings Inc
Balance Sheet Decomposition
Medpace Holdings Inc
Current Assets | 1B |
Cash & Short-Term Investments | 656.9m |
Receivables | 311.5m |
Other Current Assets | 64.2m |
Non-Current Assets | 1.1B |
PP&E | 254.6m |
Intangibles | 697.1m |
Other Non-Current Assets | 99.7m |
Current Liabilities | 1B |
Accounts Payable | 26.2m |
Accrued Liabilities | 330.5m |
Other Current Liabilities | 684.7m |
Non-Current Liabilities | 161.3m |
Other Non-Current Liabilities | 161.3m |
Earnings Waterfall
Medpace Holdings Inc
Revenue
|
2.1B
USD
|
Cost of Revenue
|
-1.5B
USD
|
Gross Profit
|
614.8m
USD
|
Operating Expenses
|
-206m
USD
|
Operating Income
|
408.8m
USD
|
Other Expenses
|
-43.2m
USD
|
Net Income
|
365.6m
USD
|
Free Cash Flow Analysis
Medpace Holdings Inc
USD | |
Free Cash Flow | USD |
In Q3 2024, the company reported revenues of $533.3 million, an 8.3% increase year-over-year, with a year-to-date total of $1.57 billion, up 13.3%. However, net new business awards fell 12.7%, leading to a book-to-bill ratio of 1.0. The company has a backlog of approximately $2.9 billion, projected to generate $1.62 billion in revenue over the next year. Full year revenue guidance is adjusted to $2.09-2.13 billion, reflecting 10.8-12.9% growth. EBITDA is anticipated between $450-470 million, a 24.1-29.7% increase from last year. Elevated cancellations, especially from projects initiated during the COVID funding surge, remain a significant concern.
What is Earnings Call?
MEDP Profitability Score
Profitability Due Diligence
Medpace Holdings Inc's profitability score is 74/100. The higher the profitability score, the more profitable the company is.
Score
Medpace Holdings Inc's profitability score is 74/100. The higher the profitability score, the more profitable the company is.
MEDP Solvency Score
Solvency Due Diligence
Medpace Holdings Inc's solvency score is 68/100. The higher the solvency score, the more solvent the company is.
Score
Medpace Holdings Inc's solvency score is 68/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MEDP Price Targets Summary
Medpace Holdings Inc
According to Wall Street analysts, the average 1-year price target for MEDP is 362.35 USD with a low forecast of 308.05 USD and a high forecast of 424.2 USD.
Dividends
Current shareholder yield for MEDP is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
MEDP Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The company is headquartered in Cincinnati, Ohio and currently employs 4,500 full-time employees. The company went IPO on 2016-08-11. The firm is focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The firm partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The firm's drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Its operations are based in North America, Europe, and Asia.
Contact
IPO
Employees
Officers
The intrinsic value of one MEDP stock under the Base Case scenario is 286.45 USD.
Compared to the current market price of 337.75 USD, Medpace Holdings Inc is Overvalued by 15%.